Lowering the diagnostic criteria for hypertension? More than 200 million incremental patients, hundreds of billions of tracks to make waves

The reduction of the judgment standard means that the threshold of hypertension treatment is moved forward, which is similar to the determination of normal high blood pressure in the current national standard, and the starting point of both standards is good, which is a warning and reminder
for this part of the group.

The New Guidelines have clear classification guidance for this group and add the content of non-drug treatment, rather than blindly administering drug treatment
when the standard value is reached.
Lifestyle interventions are also important treatment links, and both chronic disease management and digital therapeutics can play an important
role in it.

In the "New Guidelines", blood pressure values ≥ 140/90mmHg and in the range of 130~139/80~89mmHg, with clinical comorbidities, target organ damage or ≥ three cardiovascular risk factors are judged as high-risk patients; For groups with blood pressure values only in the range of 130~139/80~89mmHg and no remaining judgment conditions, they are classified as non-high-risk patients
.

Important factors to determine whether hypertensive patients are at high risk, source "New Guidelines"

For non-high-risk patients, the new guidelines recommend lifestyle interventions for 3~6 months, and then enter the drug treatment stage
if the blood pressure value cannot reach the standard.

Life interventions included diet interventions, exercise interventions, stress reduction interventions, weight loss interventions, smoking cessation and alcohol restriction, and comprehensive lifestyle
interventions.
From another perspective, the links that were previously overlooked by patients are highlighted
here.
This means that chronic disease management and digital therapeutics can play an important role
in this field in the future.

In the past, chronic disease management faced a big problem, they did to change a person's cognition, and then change his behavior, so that he can get lifestyle changes
.
This is not a problem for the affected group, and it is not so simple
for sub-healthy groups such as normal blood pressure values.
The general perception of such groups is that they do not feel that they are sick, so they avoid medical treatment and refuse to make changes
.

While the standard is lowered, the "New Guidelines" also gives a buffer period of 3~6 months, if it can return to normal through lifestyle intervention during this period, it is still a normal group, otherwise it will enter the drug treatment stage and officially become hypertensive patients
.
With such an official endorsement, it is easier for companies that provide relevant services to educate patients and thus implement services
.

Life intervention content of non-high-risk patients, source "New Guidelines"

In addition, just as digital therapeutics for diabetes have led to the development of CGM, chronic disease management for hypertension is likely to drive the ambulatory blood pressure monitoring market in the future
.

Ambulatory blood pressure monitoring (ABPM) is the "gold standard" for diagnosing hypertension, examiners need to wear blood pressure measurement equipment, measure blood pressure every 15~20 minutes during the day, and measure blood pressure every half hour at night, so that more comprehensive ambulatory blood pressure data can be obtained, which is convenient for doctor diagnosis
.

Because of this, some manufacturers began to introduce the concept of ambulatory blood pressure monitoring into the home electronic blood pressure monitor, through the upgrade iteration of the function and the optimization of the volume, so that patients can use the home electronic blood pressure monitor can also perform a certain degree of ambulatory blood pressure monitoring services
.

In addition to the function, the convenience of use is also the direction of
the manufacturer's efforts.
Compared with the almost insensible CGM, no matter how to optimize the integrated design of the host cuff of the home electronic blood pressure monitor, it still lacks
in wearing comfort.
Therefore, many manufacturers pin their solutions on wearable devices
.
The Guidelines for the Registration Review of Remote Monitoring Systems (Draft for Comments) issued by the State Food and Drug Administration (NMPA) at the end of August also reflect the policy attitude that wearable medical devices will play an increasingly important role
in medical treatment in the future.

With the development of technology, wearables have made tremendous progress
.
From heart rate to ECG, blood oxygen to blood pressure, wearables can already continuously monitor with medical precision the signs signals
that play a key role in the diagnosis and treatment of these diseases.

In recent years, Huawei, Samsung, Huami, Kangkang Blood Pressure, Yanhe Intelligent and other companies have successively launched smart watches with blood pressure detection functions, including technology giants and start-ups
.
Compared with the traditional arm and wrist blood pressure monitors, the products in the form of watches are more comfortable to wear and almost non-sensory applications
.

Smart watch blood pressure monitoring is a very difficult technology, in order to ensure a certain accuracy, not only need to monitor the pulse wave beating frequency, but also collect pulse wave structure information, morphological information and other information comprehensive analysis, and wearer skin color, skin condition, action, behavior and other external factors will affect the results
.
The existence of technical barriers makes the vertical field of blood pressure monitoring still in a blue ocean
in the wearable device market.

In the future, with the increase of audience groups, market demand may usher in explosive growth, and wearable devices in the field of blood pressure monitoring will be further popularized
with the landing of digital therapy.

It is difficult to expand the market of antihypertensive drugs in the 100 billion yuan